You are here: Industry Insights > siltuximab

News List

EUSA Pharma launches phase III COVID-19 study for siltuximab pharmatimes
December 18, 2020
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.
EUSA Pharma bags US approval for COVID-19 trial pharmatimes
July 03, 2020
US regulators have issued a green light for a Phase III clinical trial testing EUSA Pharma's for patients seriously ill with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Positive early data from siltuximab COVID-19 trial pharmatimes
April 02, 2020
A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, according to early findings from an observational case-control trial in Italy.
Study evaluates if siltuximab benefits COVID-19 patients with respiratory complications europeanpharmaceuticalreview
March 23, 2020
The SISCO study will assess if the anti-IL-6 antibody siltuximab can aid patients suffering Acute Respiratory Distress Syndrome as a complication of the COVID-19 coronavirus.